Women with polycystic ovarian syndrome (PCOS) who have a BMI of 25 kg/m² or above face compounded metabolic challenges that require specific clinical attention beyond standard PCOS management. In this sub-population, addressing weight and metabolic outcomes is a central treatment objective.
This protocol applies to adult women with PCOS and BMI ≥ 25 kg/m² in whom management of weight and metabolic outcomes is indicated. The elevated BMI is the defining clinical feature shaping the treatment approach in this scenario.
The protocol combines lifestyle modification with a pharmacological agent to address weight, hormonal, and metabolic outcomes. The specific agent involved, the structured way in which it is introduced, and how it is adjusted over time are laid out in the complete regimen.